Drugs / STX-1150
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07428473 | Jun 2026 → Dec 2028 expected | low density lipoprotein cholesterol, mild elevation of | Monash University | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-05-28 | Scribe Therapeutics Inc. | Results Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose scribetx.com ↗ |
| 2026-05-21 | Scribe Therapeutics Inc. | Regulatory Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction scribetx.com ↗
today announced that it has secured clearance from the Australian Therapeutic Goods Administration (TGA) to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia |
| 2025-11-17 | Scribe Therapeutics Inc. | Results Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025 scribetx.com ↗
Targeted epigenetic silencing therapy, STX-1150, achieved a ≥ 50% reduction in LDL-C for over 515 days in primates after a single, therapeutically relevant dose, establishing translational proof-of-concept for a novel therapeutic approach that does not alter the underlying genetic code |
| 2025-05-22 | Scribe Therapeutics Inc. | Results Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting scribetx.com ↗
At a therapeutically relevant dose of 0.75 mg/kg, the STX-1150 prototype lowers LDL-C by >50% and demonstrates a favorable tolerability profile, positioning it as a potentially safe and effective treatment option for LDL-C lo |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STX-1150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07428473 ↗ |
| Action | Inhibit | “STX-1150 epigenetically silences the expression of the PCSK9 gene in the liver” NCT07428473 ↗ |
| Target | PCSK9 | “STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver.” NCT07428473 ↗ |